Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 590,000 |
50 mg | 約10-14 週間 | ¥ 776,000 |
100 mg | 約10-14 週間 | ¥ 1,056,000 |
In vivo | Administering Implitapide (3.2 mg/kg/d) significantly inhibits lipid-stained lesions in mice on a Western-type diet (WD), reducing lesion area by 83% compared to the WD group (p<0.01) and substantially lowering plasma lipid levels to near or below those on a chow diet (CD) at both 4 and 8 weeks of treatment (p<0.01). Furthermore, this dosage of Implitapide markedly reduces lipid-stained aortic lesions by 83% in apoE knockout (KO) mice. In addition, apoE KO mice fed a WD supplemented with varying doses of Implitapide (1, 5, and 15 mg/kg/d) for 14 weeks exhibit a significant decrease in both plaque area (66, 78, and 93% reduction, respectively) and lipid content within plaques (to 4.3, 2.6, and 0%, respectively, compared with 9.5% in controls)[1]. |
別名 | AEGR 427 |
分子量 | 531.69 |
分子式 | C35H37N3O2 |
CAS No. | 177469-96-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Implitapide 177469-96-4 Metabolism CETP AEGR427 AEGR 427 AEGR-427 Inhibitor inhibitor inhibit